Literature DB >> 11920959

Complex functions of mutant p53 alleles from human prostate cancer.

Xu-Bao Shi1, Nancy J Nesslinger, Arline D Deitch, Paul H Gumerlock, Ralph W deVere White.   

Abstract

BACKGROUND: Few studies have used multiple assays to examine the functionality of mutant p53 in prostate cancer (CaP). We employed seven functional assays to study 16 representative mutant p53 alleles, six from localized and ten from metastatic CaP.
METHODS: Yeast assays were employed to determine loss of function (LOF), partial function (PF), and dominant-negative status. Assays using p53-null Saos2 cells were used to determine whether mammalian cells transfected with mutant p53 could up-regulate the MDR-1 or PCNA promoters, alter IL-6 expression or confer the ability to grow in soft agar. As a further test of gain of function (GOF), p53-null PC3 cells stably transfected with these mutant p53 alleles were examined for cell cycle distributions.
RESULTS: All 16 mutant p53 alleles demonstrated either total or partial LOF. All but one allele also had at least one gain of function; however, the pattern of GOF was different for each mutant allele. Alleles derived from both localized and metastatic CaP had similar GOF characteristics; however, only alleles from metastatic disease had significantly increased S-phase fractions.
CONCLUSIONS: Different mutant p53 alleles from CaP had different, complex functional profiles. The lack of predictable patterns for these alleles suggest that each mutation may uniquely affect p53 function. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920959     DOI: 10.1002/pros.10072

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  16 in total

1.  Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.

Authors:  Andrew J Davies; Andreas Rosenwald; George Wright; Abigail Lee; Kim W Last; Dennis D Weisenburger; Wing C Chan; Jan Delabie; Rita M Braziel; Elias Campo; Randy D Gascoyne; Elaine S Jaffe; Konrad Muller-Hermelink; German Ott; Maria Calaminici; Andrew J Norton; Lindsey K Goff; Jude Fitzgibbon; Louis M Staudt; T Andrew Lister
Journal:  Br J Haematol       Date:  2007-01       Impact factor: 6.998

Review 2.  Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

Authors:  Brian D Lehmann; James A McCubrey; David M Terrian
Journal:  Cancer Biol Ther       Date:  2007-08-05       Impact factor: 4.742

3.  TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.

Authors:  Alexandra M Blee; Yundong He; Yinhui Yang; Zhenqing Ye; Yuqian Yan; Yunqian Pan; Tao Ma; Joseph Dugdale; Emily Kuehn; Manish Kohli; Rafael Jimenez; Yu Chen; Wanhai Xu; Liguo Wang; Haojie Huang
Journal:  Clin Cancer Res       Date:  2018-05-29       Impact factor: 12.531

4.  Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.

Authors:  I Kogan-Sakin; Y Tabach; Y Buganim; A Molchadsky; H Solomon; S Madar; I Kamer; P Stambolsky; A Shelly; N Goldfinger; S Valsesia-Wittmann; A Puisieux; A Zundelevich; E N Gal-Yam; C Avivi; I Barshack; M Brait; D Sidransky; E Domany; V Rotter
Journal:  Cell Death Differ       Date:  2010-08-06       Impact factor: 15.828

5.  Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells.

Authors:  Tong-Xin Xie; Ge Zhou; Mei Zhao; Daisuke Sano; Samar A Jasser; Richard G Brennan; Jeffrey N Myers
Journal:  Laryngoscope       Date:  2013-04-26       Impact factor: 3.325

6.  p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.

Authors:  Catherine A Vaughan; Shilpa Singh; Brad Windle; Heidi M Sankala; Paul R Graves; W Andrew Yeudall; Swati P Deb; Sumitra Deb
Journal:  Arch Biochem Biophys       Date:  2011-12-16       Impact factor: 4.013

Review 7.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

8.  Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.

Authors:  Catherine A Vaughan; Shilpa Singh; Brad Windle; W Andrew Yeudall; Rebecca Frum; Steven R Grossman; Swati P Deb; Sumitra Deb
Journal:  Genes Cancer       Date:  2012-07

9.  Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

Authors:  Chih-Jian Lih; David J Sims; Robin D Harrington; Eric C Polley; Yingdong Zhao; Michele G Mehaffey; Thomas D Forbes; Biswajit Das; William D Walsh; Vivekananda Datta; Kneshay N Harper; Courtney H Bouk; Lawrence V Rubinstein; Richard M Simon; Barbara A Conley; Alice P Chen; Shivaani Kummar; James H Doroshow; Paul M Williams
Journal:  J Mol Diagn       Date:  2015-11-18       Impact factor: 5.568

10.  Iron deprivation induces apoptosis independently of p53 in human and murine tumour cells.

Authors:  J Truksa; J Kovár; T Valenta; M Ehrlichová; J Polák; P W Naumann
Journal:  Cell Prolif       Date:  2003-08       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.